Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$8.29 USD
+0.03 (0.36%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $8.28 -0.01 (-0.12%) 4:36 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.29 USD
+0.03 (0.36%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $8.28 -0.01 (-0.12%) 4:36 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Zacks.com featured highlights include Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences
by Zacks Equity Research
Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.
Sail Through the Choppy Market With These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.
Can Maravai LifeSciences Holdings, Inc. (MRVI) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Maravai LifeSciences Holdings, Inc. (MRVI) Climb 56% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 55.8% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 18.42% and 10.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Maravai LifeSciences Holdings, Inc. (MRVI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Maravai LifeSciences Holdings, Inc. (MRVI) and Repligen (RGEN) have performed compared to their sector so far this year.
3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022
by Debanjana Dey
Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.
Philips (PHG) to Buy Vesper Medical, Expand Vascular Portfolio
by Zacks Equity Research
Philips (PHG) is set to acquire Vesper Medical to strengthen its vascular devices portfolio and customer base.
Is LabCorp (LH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.
Earnings Estimates Moving Higher for Maravai LifeSciences Holdings, Inc. (MRVI): Time to Buy?
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Maravai LifeSciences Holdings, Inc. (MRVI) Climb 25% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 25.1% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has LabCorp (LH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.
How Much Upside is Left in Maravai LifeSciences (MRVI)? Wall Street Analysts Think 40%
by Zacks Equity Research
The consensus price target hints at a 40.2% upside potential for Maravai LifeSciences (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
New Strong Buy Stocks for October 8th
by Zacks Equity Research
CNXC, DLTH, NVEE, MRVI, and PFSI have been added to the Zacks Rank #1 (Strong Buy) List on October 8, 2021.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Faster adoption of digital health and an improved business environment are expected to have contributed to Walgreens' (WBA) fourth-quarter performance.
3 High-Potential MedTech Stocks With More Than 50% Growth YTD
by Riya Anand
Stocks like West Pharmaceuticals Services (WST), Maravai LifeSciences (MRVI) and Option Care Health (OPCH) have gained stupendously year to date.
Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Momentum Stocks to Buy for August 13th
by Zacks Equity Research
MRVI, DSKE, VRTS, and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 13, 2021.
NVIDIA, Lumentum, Maravai LifeSciences, Baxter International and BellRing Brands highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
NVIDIA, Lumentum, Maravai LifeSciences, Baxter International and BellRing Brands highlighted as Zacks Bull and Bear of the Day
Child Health in Focus in Face of Delta Strain Threat: 3 Picks
by Urmimala Biswas
Here are three stocks, BAX, BRBR, and MRVI with a favorable Zacks Rank and huge prospects in child healthcare at present.
The Zacks Analyst Blog Highlights: Henry Schein, BellRing Brands, Maravai LifeSciences and National Vision Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Henry Schein, BellRing Brands, Maravai LifeSciences and National Vision Holdings
4 Safe MedTech Bets Before Delta Strain Disrupts the Market Again
by Urmimala Biswas
Here are four MedTech stocks, HSIC, BRBR, MRVI and EYE, with favorable Zacks Rank and stellar growth parameters.
The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein
by Zacks Equity Research
The Zacks Analyst Blog Highlights: National Vision Holdings, Maravai LifeSciences, Sonova Holding, Sartorius and Henry Schein
5 MedTech Stocks to Gain in 2021 as Base Business Recovers
by Urmimala Biswas
These five MedTech stocks, EYE, MRVI, SONVY, SARTF and HSIC, all with a favorable Zacks Rank and growth parameters are expected to put up a robust performance in 2021.